Corpus overview


Overview

MeSH Disease

Diarrhea (28)

Fever (23)

Fatigue (15)

Infections (15)

Cough (13)


Human Phenotype

Diarrhea (29)

Fever (24)

Cough (24)

Fatigue (14)

Headache (8)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 29
    records per page




    Clinical characteristics of pediatric cases of SARS-CoV-2 infection MESHD in Hunan, China: A retrospective, multi-center case series

    Authors: Lei Wu; Xiao-Fo Zhang; Jia Li; Song-Qing Wei; Yong Yang; Xiu-Ying Yi; Xin-Ping Jiang; Hai-Ying Han; Zhe-Feng Zhong; Xiao-Ying Cao; Feng-Jun L; Ge Zhou; Xiao-Hui Gong; Wen-Ting Zha; He-Bin Xie; Tuan-Mei Wang; Man-Zhi Wang

    doi:10.21203/rs.3.rs-78282/v1 Date: 2020-09-15 Source: ResearchSquare

    Objective To investigate the epidemiological characteristics, clinical features, treatment and short-term prognosis of SARS-CoV-2 infection MESHD in children TRANS.Methods A retrospective analysis was conducted in children TRANS with SARS-CoV-2 admitted to twelve hospitals in eight cities in Hunan province, China, from January 26, 2020 to June 30, 2020.Results A total of 48 children were enrolled in this study. 11 cases (23%) were asymptomatic TRANS, 15 cases (31%) were mild, 20 cases (42%) were moderate, and 2 cases (4%) were severe. No children TRANS were critical requiring intensive care. The most common symptom was fever HP fever MESHD (42%), cough HP (40%), fatigue MESHD (17%) and diarrhea HP diarrhea MESHD (10%). The total peripheral blood SERO leukocytes count decreased in two case (4%), Lymphocytopenia MESHD was present in 5 cases (10%). There were abnormal chest CT changes in 22 children (46%), including 15 (68%) with patchy ground glass opacity. In addition to supportive treatment, 41 children TRANS (85%) received antiviral therapy, 11 patients and (23%) were treated with antibiotics, 2 children TRANS (4%) were treated with methylprednisolone and IVIG. There was no death occurred.Conclusions Most children TRANS with SARS CoV-2 infection MESHD in Hunan province were asymptomatic TRANS, mild or moderate. Severe cases are rare. Close family contact was the main route of infection MESHD. The younger the age TRANS, the less obvious symptoms for children TRANS might be. Epidemiological history, nucleic acid test and chest imaging were important tools for the diagnosis in children TRANS.

    SARS-CoV-2-specific IgA and limited inflammatory cytokines are present in the stool of select patients with acute COVID-19

    Authors: Graham J Britton; Alice Chen-Liaw; Francesca Cossarini; Alexandra E Livanos; Matthew P Spindler; Tamar Plitt; Joseph Eggers; Ilaria Mogno; Ana Gonzalez-Reiche; Sophia Siu; Michael Tankelevich; Lauren Grinspan; Rebekah E Dixon; Divya Jha; Gustavo Martinez-Delgado; Fatima Amanat; Daisy A Hoagland; Benjamin tenOever; Marla C Dubinsky; Miriam Merad; Harm van Bakel; Florian Krammer; Gerold Bongers; Saurabh Mehandru; Jeremiah J Faith

    doi:10.1101/2020.09.03.20183947 Date: 2020-09-05 Source: medRxiv

    Background and aims: Immune dysregulation HP dysregulation MESHD caused by SARS-CoV-2 infection MESHD is thought to play a pathogenic role in COVID-19. SARS-CoV-2 can infect a variety of host cells, including intestinal epithelial cells. We sought to characterize the role of the gastrointestinal immune system in the pathogenesis of the inflammatory response associated with COVID-19. Methods: We measured cytokines, inflammatory markers, viral RNA, microbiome composition and antibody SERO responses in stool and serum samples SERO from a prospectively enrolled cohort of 44 hospitalized COVID-19 patients. Results: SARS-CoV-2 RNA was detected in stool of 41% of patients and was found more frequently in patients with diarrhea HP diarrhea MESHD than those without (16[44%] vs 5[19%], p=0.06). Patients who survived had lower median viral genome copies than those who did not (p=0.021). Compared to uninfected controls, COVID-19 patients had higher median fecal levels of IL-8 (166.5 vs 286.5 pg/mg; p=0.05) and lower levels of fecal IL-10 (678 vs 194 pg/mg; p<0.001) compared to uninfected controls. Stool IL-23 was higher in patients with more severe COVID-19 disease (223.8 vs 86.6 pg/mg; p=0.03) and we find evidence of intestinal virus-specific IgA responses, which was associated with more severe disease. Fecal cytokines and calprotectin levels were not correlated with gastrointestinal symptoms MESHD or with the level of virus detected. Conclusions: Although SARS-CoV-2 RNA was detectable in the stools of COVID-19 patients and select individuals had evidence for a specific mucosal IgA response, intestinal inflammation MESHD was limited, even in patients presenting with gastrointestinal symptoms MESHD.

    Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial

    Authors: Maria Isabel F Lopes; Leticia P Bonjorno; Marcela C Giannini; Natalia B Amaral; Maira N Benatti; Uebe C Rezek; Laerte L Emrich-Filho; Betania AA Sousa; Sergio CL Almeida; Rodrigo Luppino-Assad; Flavio P Veras; Ayda Schneider; Tamara S Rodrigues; Luiz OS Leiria; Larissa D Cunha; Jose C Alves-Filho; Thiago M Cunha; Eurico Arruda Neto; Carlos H Miranda; Antonio Pazin-Filho; Maria A Martins; Marcos C Borges; Benedito AL Fonseca; Valdes R Bollela; Cristina M Del-Ben; Fernando Q Cunha Sr.; Dario S Zamboni; Rodrigo C Santana; Fernando C Vilar; Paulo Louzada-Junior; Rene D R Oliveira

    doi:10.1101/2020.08.06.20169573 Date: 2020-08-11 Source: medRxiv

    Introduction. Neutrophilia HP and high levels of proinflammatory cytokines and other mediators of inflammation MESHD are common finds in patients with severe acute respiratory syndrome MESHD due to COVID-19. By its action on leukocytes, we propose colchicine as an intervention worthy of being tested. Objective. To evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes. Methods. We present the interim analysis of a single-center randomized, double-blinded, placebo controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 38 patients allocated 1:1 from April 11 to July 06, 2020. Colchicine regimen was 0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days. The first dose was 1.0 mg whether body weight was [≥] 80 kg. Endpoints. The primary endpoints were the need for supplemental oxygen; time of hospitalization; need for admission and length of stay in intensive care units; and death rate and causes of mortality. As secondary endpoints, we assessed: serum SERO C-reactive protein, serum SERO Lactate dehydrogenase and relation neutrophil to lymphocyte of peripheral blood SERO samples from day zero to day 7; the number, type, and severity of adverse events; frequency of interruption of the study protocol due to adverse events; and frequency of QT interval above 450 ms. Results. Thirty-five patients (18 for Placebo and 17 for Colchicine) completed the study. Both groups were comparable in terms of demographic, clinical and laboratory data at baseline. Median (and interquartile range) time of need for supplemental oxygen was 3.0 (1.5-6.5) days for the Colchicine group and 7.0 (3.0-8.5) days for Placebo group (p = 0.02). Median (IQR) time of hospitalization was 6.0 (4.0-8.5) days for the Colchicine group and 8.5 (5.5-11.0) days for Placebo group (p = 0.03). At day 2, 53% vs 83% of patients maintained the need for supplemental oxygen, while at day 7 the values were 6% vs 39%, in the Colchicine and Placebo groups, respectively (log rank; p = 0.01). Hospitalization was maintained for 53% vs 78% of patients at day 5 and 6% vs 17% at day 10, for the Colchicine and Placebo groups, respectively (log rank; p = 0.01). One patient per group needed admission to ICU. No recruited patient died. At day 4, patients of Colchicine group presented significant reduction of serum SERO C-reactive protein compared to baseline (p < 0.001). The majority of adverse events were mild and did not lead to patient withdrawal. Diarrhea HP Diarrhea MESHD was more frequent in the Colchicine group (p = 0.17). Cardiac adverse events were absent. Discussion. The use of colchicine reduced the length of supplemental oxygen therapy and the length of hospitalization. Clinical improvement was in parallel with a reduction on serum SERO levels of C-reactive protein. The drug was safe and well tolerated. Colchicine may be considered a beneficial and not expensive option for COVID-19 treatment. Clinical trials with larger numbers of patients should be conducted to further evaluate the efficacy and safety of colchicine as an adjunctive therapy for hospitalized patients with moderate to severe COVID-19.

    Clinical and intestinal histopathological findings in SARS-CoV-2/COVID-19 patients with hematochezia HP hematochezia MESHD

    Authors: Margaret Cho; Weiguo Liu; Sophie Balzora; Yvelisse Suarez; Deepthi Hoskoppal; Neil D Theise; Wenqing Cao; Suparna A Sarkar

    doi:10.1101/2020.07.29.20164558 Date: 2020-08-07 Source: medRxiv

    Gastrointestinal ( GI MESHD) symptoms of SARS-CoV2/COVID-19 in the form of anorexia HP anorexia MESHD, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, abdominal pain HP abdominal pain MESHD and diarrhea HP diarrhea MESHD are usually preceeded by respiratory manifestations and are associated with a poor prognosis. Hematochezia HP Hematochezia MESHD is an uncommon clinical presentation of COVID-19 disease and we hypothesize that older patients with significant comorbidites ( obesity HP obesity MESHD and cardiovascular) and prolonged hospitalization are suspectible to ischemic injury MESHD to the bowel. We reviewed the clinical course, key laboratory data including acute phase reactants, drug/medication history in two elderly TRANS male TRANS patients admitted for COVID-19 respiratory failure HP respiratory failure MESHD. Both patients had a complicated clinical course and suffered from hematochezia HP hematochezia MESHD and acute blood SERO blood MESHD loss anemia HP requiring blood SERO transfusion around day 40 of their hospitalization. Colonoscopic impressions were correlated with the histopathological findings in the colonic biopies and changes compatible with ischemia MESHD to nonspecific acute inflammation MESHD, edema HP edema MESHD and increased eosinophils in the lamina propria were noted.Both patients were on anticoagulants, multiple antibiotics and antifungal agents due to respiratory infections MESHD at the time of lower GI bleeding MESHD. Hematochezia HP Hematochezia MESHD resolved spontaneously with supportive care. Both patients eventually recovered and were discharged. Elderly TRANS patients with significant comorbid conditions are uniquely at risk for ischemic injury MESHD to the bowel. Hypoxic conditions MESHD due to COVID-19 pneumonia HP pneumonia MESHD and respiratory failure HP respiratory failure MESHD, compounded by preexisting cardiovascular complications, and/or cytokine storm orchestrated by the viral infection leading to alteration in coagulation profile and/or drug/medication injury can be difficult to distinguish in these critically ill patients. Presentation of hematochezia HP hematochezia MESHD may further increase the mortality and morbidity of COVID-19 patients, and prompt consultation and management by gastroenterology is therefore warranted.

    Rapid host response to an infection with Coronavirus. Study of transcriptional responses with Porcine Epidemic Diarrhea HP Diarrhea MESHD Virus

    Authors: Wei Hou; Fei Liu; Wim H.M. van der Poel; Marcel M Hulst

    doi:10.1101/2020.07.28.224576 Date: 2020-07-28 Source: bioRxiv

    The transcriptional response in Vero cells (ATCC(R) CCL-81) infected with the coronavirus Porcine Epidemic Diarrhea Virus MESHD Diarrhea HP Virus (PEDV) was measured by RNAseq analysis 4 and 6 hours after infection MESHD. Differential expressed genes (DEGs) in PEDV infected cells were compared to DEGs responding in Vero cells infected with Mammalian Orthoreovirus (MRV). Functional analysis of MRV and PEDV DEGs showed that MRV increased the expression level of several cytokines and chemokines (e.g. IL6, CXCL10, IL1A, CXCL8 [alias IL8]) and antiviral genes (e.g. IFI44, IFIT1, MX1, OASL), whereas for PEDV no enhanced expression was observed for these "hallmark" antiviral and immune effector genes. Pathway and Gene Ontology "enrichment analysis" revealed that PEDV infection MESHD did not stimulate expression of genes able to activate an acquired immune response, whereas MRV did so within 6h. Instead, PEDV down-regulated the expression of a set of zinc finger proteins with putative antiviral activity and enhanced the expression of the transmembrane serine protease gene TMPRSS13 (alias MSPL) to support its own infection by virus-cell membrane fusion (Shi et al, 2017, Viruses, 9(5):114). PEDV also down-regulated expression of Ectodysplasin A, a cytokine of the TNF-family able to activate the canonical NFKB-pathway responsible for transcription of inflammatory genes like IL1B, TNF, CXCL8 and PTGS2. The only 2 cytokine genes found up-regulated by PEDV were Cardiotrophin-1, an IL6-type cytokine with pleiotropic functions on different tissues and types of cells, and Endothelin 2, a neuroactive peptide with vasoconstrictive properties. Furthermore, by comprehensive datamining in biological and chemical databases and consulting related literature we identified sets of PEDV-response genes with potential to influence i) the metabolism of biogenic amines (e.g. histamine), ii) the formation of cilia and "synaptic clefts" between cells, iii) epithelial mucus production, iv) platelets activation, and v) physiological processes in the body regulated by androgenic hormones (like blood SERO pressure, salt/water balance and energy homeostasis). The information in this study describing a "very early" response of epithelial cells to an infection MESHD with a coronavirus may provide pharmacologists, immunological and medical specialists additional insights in the underlying mechanisms of coronavirus associated severe clinical symptoms including those induced by SARS-CoV-2. This may help them to fine-tune therapeutic treatments and apply specific approved drugs to treat COVID-19 patients.

    COVID-19 Case Series at UnityPoint Health St. Lukes Hospital in Cedar Rapids, IA

    Authors: Daniel E McGrail; Dianna Edwards

    doi:10.1101/2020.07.17.20156521 Date: 2020-07-19 Source: medRxiv

    A retrospective, descriptive study of all patients tested for SARS-CoV2 on admission for illness to a community hospital in Iowa from 3/21/20 thru 6/14/20 consisted of evaluation as to demographics, presentation and hospital course. Ninety-one patients were SARS-CoV2 PCR+ with 63% being male TRANS and a median age TRANS of 60. Cardiovascular disease MESHD was a significant comorbidity in the PCR+ group. Fever HP Fever MESHD, cough HP cough MESHD, dyspnea HP dyspnea MESHD, nausea HP nausea MESHD, emesis MESHD, diarrhea HP diarrhea MESHD, headache HP headache MESHD and myalgias HP myalgias MESHD were significantly more common in that group, as was an elevated CRP, LDH, serum SERO ferritin and transaminases. Overall survival of the COVID-19 patients was 88%, 77% in the critically ill, 59% of those mechanically ventilated and 33% of those requiring new dialysis. Survival was 93% in those not receiving any antivirals. Survival of those treated with hydroxychloroquine-azithromycin was 92%, compared to 86% of those treated with hydroxychloroquine alone. The latter two groups were significantly more ill than the untreated group. A transition from an early intubation strategy to aggressive utilization of high flow nasal cannula and noninvasive ventilation(i.e BiPAP) was successful in freeing up ICU resources.

    Analysis of the Primary Presenting Symptoms and Hematological Findings of COVID-19 Patients in Bangladesh

    Authors: Abu Taiub Mohammed Mohiuddin Chowdhury; Md Rezaul Karim; H.M. Hamidullah Mehedi; Mohammad Shahbaz; Md Wazed Chowdhury; Guo Dan; Shuixiang He

    id:10.20944/preprints202006.0275.v1 Date: 2020-06-21 Source: Preprints.org

    Objective: SARS-Cov-2 infection MESHD or COVID-19 is a global pandemic. From the time of identification to till, multiple clinical symptoms and parameters have been identified by the researchers of various countries and regions regarding the diagnosis and presentations of COVID-19 disease. In this manuscript, we investigated the primary symptoms and basic hematological presentations of SARS-CoV-2 infection MESHD among the Bangladeshi patients. Methodology: We have collected the disease history of mild to moderate degree of COVID-19 patients; hematological MESHD and biochemical on admission reports of moderate degree COVID-19 patients. All of them were tested positive for SARS-CoV-2 by RT-PCR in different institutes in Bangladesh. Results: According to this study though COVID-19 patients in Bangladesh commonly presented with fever HP fever MESHD, cough HP cough MESHD, fatigue HP fatigue MESHD, shortness of breath MESHD, and sore throat, but symptoms like myalgia HP myalgia MESHD, diarrhea HP diarrhea MESHD, skin rash HP skin rash MESHD, headache HP headache MESHD, Abdominal pain HP Abdominal pain MESHD/cramp, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, restlessness HP, and a higher temperature of >1000F have a greater presentation rate and more frequent than other published studies. CRP and Prothrombin time was found to increase in all the patients. Serum SERO ferritin, ESR, SGPT, and D-Dimer were found increased among 53.85%, 80.43, 44%, and 25% patients respectively. 17.39% of the patients had leukocytosis HP leukocytosis MESHD and neutrophilia HP. 28.26% of patients presented with lymphocytopenia MESHD. 62.52% of patients had mild erythrocytopenia. Conclusion: Despite some similarities, our study has evaluated a different expression in presenting symptoms in the case of COVID-19 patients in Bangladesh. CRP, Prothrombin time, serum SERO ferritin, ESR, SGPT, D-Dimer, erythrocytopenia, and lymphocytopenia MESHD can be initial diagnostic hematological findings and assessment for prognosis COVID-19 disease. Also, gender TRANS variations have a different scenario of clinical and laboratory appearance in this region.

    "Analysis of the Primary Presenting Symptoms and Hematological Findings of COVID19 Patients in Bangladesh"

    Authors: Abu Taiub Mohammed Mohiuddin Chowdhury; Md Rezaul Karim; H.M.Hamidullah Mehedi; Mohammad Shahbaz; Md Wazed Chowdhury; Dan Guo; Shuixiang He

    doi:10.21203/rs.3.rs-35016/v1 Date: 2020-06-12 Source: ResearchSquare

    Background:SARS-Cov-2 infection MESHD or COVID-19 is a global pandemic. From the time of identification to till, multiple clinical symptoms and parameters have been identified by the researchers of various countries and regions regarding the diagnosis and presentations of COVID19 disease. In this manuscript, we investigated the primary symptoms and basic hematological presentations of SARS-CoV-2 infection MESHD among the Bangladeshi patients. Methodology: We have collected the disease history of mild to moderate degree of COVID19 patients; hematological MESHD and biochemical on admission reports of moderate degree COVID19 patients.  All of them were tested positive for SARS-CoV-2 by RT PCR in different institutes in Bangladesh. Results: According to this study though COVID19 patients in Bangladesh commonly presented with fever HP fever MESHD, cough HP cough MESHD, fatigue HP fatigue MESHD, shortness of breath MESHD, and sore throat, but symptoms like myalgia HP myalgia MESHD, diarrhea HP diarrhea MESHD, skin rash HP skin rash MESHD, headache HP headache MESHD, Abdominal pain HP Abdominal pain MESHD/cramp, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, restlessness HP, and a higher temperature of >1000F have a greater presentation rate and more frequent than other published studies. CRP and Prothrombin time was found to increase in all the patients. Serum SERO ferritin, ESR, SGPT, and D-Dimer were found increased among 53.85%, 80.43, 44%, and 25% patients respectively. 17.39% of the patients had leucocytosis and neutrophilia HP. 28.26% of patients presented with lymphocytopenia MESHD. 62.52% of patients had mild erythrocytopenia. Conclusion: Despite some similarities, our study has evaluated a different expression in presenting symptoms in the case of COVID19 patients in Bangladesh. CRP, Prothrombin time, serum SERO ferritin, ESR, SGPT, D-Dimer, erythrocytopenia, and lymphocytopenia MESHD can be initial diagnostic hematological findings and assessments for prognosis COVID19 disease. Also, Gender TRANS variation has a different scenario of clinical and laboratory appearance in this region.

    Co-infection of COVID-19 and Influenza A in A Hemodialysis Patient: A Case Report

    Authors: Ran Jing; Rama R Vunnam; Elizabeth Schnaubelt; Chad Vokoun; Allison Cushman-Vokoun; David Goldner; Srinivas R Vunnam

    doi:10.21203/rs.3.rs-31135/v1 Date: 2020-05-22 Source: ResearchSquare

    Background: Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel coronavirus that was first discovered in Wuhan, China in December 2019. With the growing numbers of community spread cases worldwide, the World Health Organization (WHO) declared the COVID-19 outbreak as a pandemic on March 11. Like influenza viruses, SARS-CoV-2 is thought to be transmitted by contact, droplets, and fomites, and COVID-19 has a similar disease presentation to influenza. Here we present a case of influenza A and COVID-19 co-infection MESHD in a 60-year-old man with end-stage renal disease MESHD ( ESRD MESHD) on hemodialysis.Case presentation: A 60-year-old man with ESRD MESHD on hemodialysis (HD) presented for worsening cough HP cough MESHD, shortness of breath MESHD, and diarrhea HP diarrhea MESHD. The patient first developed a mild fever HP fever MESHD (100 °F) during hemodialysis three days prior to presentation and has been experiencing worsening flu-like symptoms, including fever HP of up to 101.6 °F, non- productive cough HP, generalized abdominal pain HP abdominal pain MESHD, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, and liquid green diarrhea HP diarrhea MESHD. He lives alone at home with no known sick contacts and denies any recent travel TRANS or visits to healthcare facilities other than the local dialysis center. Rapid flu test was positive for influenza A. Procalcitonin was elevated at 5.21 ng/mL with a normal white blood SERO cell (WBC) count. Computed tomography (CT) chest demonstrated multifocal areas of consolidation and extensive mediastinal and hilar adenopathy MESHD concerning for pneumonia HP pneumonia MESHD. He was admitted to the biocontainment unit of Nebraska Medicine for concerns of possible COVID-19 and was started on oseltamivir for influenza and vancomycin/cefepime for the probable bacterial cause of his pneumonia HP pneumonia MESHD and diarrhea HP diarrhea MESHD. GI MESHD pathogen panel and C. diff toxin assay were negative. On the second day of admission, initial nasopharyngeal swab came back positive for SARS-CoV-2 by RT-PCR. The patient received supportive care and resumed bedside hemodialysis in strict isolation, and eventually fully recovered from COVID-19.Conclusions: Our case demonstrated that co-infection of influenza and SARS-CoV-2 can occur in patients with no known direct exposure to COVID-19. The possibility of SARS-CoV-2 co-infection MESHD should not be overlooked even when other viruses including influenza can explain the clinical symptoms.

    Clinical features of COVID-19 patients in one designated medical institutions in Chengdu, China

    Authors: Gui Zhou; Yun-Hui Tan; Jiang-Cuo Luo; Yi-Xiao Lu; Jing Feng; Juan Li; Yun-Mei Yang; Long Chen; Jian-Ping Zhang

    doi:10.21203/rs.3.rs-30405/v1 Date: 2020-05-19 Source: ResearchSquare

    OBJECTIVE: To study the clinical characteristics of patients infected with the 2019 severe acute respiratory syndrome coronavirus 2 MESHD (SARS-Cov-2) responsible for coronavirus disease MESHD (COVID-2019).METHODS: Data were collected from 20 patients admitted to the Pidu District People’s Hospital in Chengdu from January 26, 2020 to March 1, 2020 with laboratory-confirmed SARS-Cov-2 infection. Clinical data were collected using the World Health Organization (WHO) nCoV CASE RECORDFORM Version 1.2 28JAN2020, which includes parameters such as: temperature, epidemiological characteristics, social network, history of exposure, and incubation period TRANS. If information was unclear, the team reviewed the original data and contacted TRANS patients directly if necessary.RESULTS: The median age TRANS of the 20 COVID-19 infected MESHD patients studied was 42.5 years. In this cohort, four patients became severely ill and one deteriorated rapidly during treatment. This patient was transferred to another medical center with an intensive care unit (ICU) for treatment. This patient died after admission to the ICU. Two of the twenty patients remained positive SARS-Cov-2 more than three weeks, and they were quarantined in a medical facility without medication. According to our analysis, all of the studied cases were infected by human-to-human transmission TRANS due to the lack of protective measures; transmission TRANS through contact within families requires confirmation. The most common symptoms at onset TRANS of illness were fever HP fever MESHD in 13 (65%) patients, cough HP in 9 (45%), headache HP headache MESHD in 3 (15%), fatigue HP fatigue MESHD in 6 (30%), diarrhea HP diarrhea MESHD in 3 (15%), and abdominal pain HP abdominal pain MESHD in 2 (10%). Six patients (30%) developed shortness of breath MESHD upon admission. The median time from exposure to onset of illness was6.5 days (interquartile range 3.25–9 days), and from the onset of symptoms TRANS to first hospital admission was 3.5 (1.25–7) days.CONCLUSION: Compared with patients infected with SARS-Cov-2 in Wuhan (up to the end of February 2020), the symptoms of patients in one hospital in Chengdu, Sichuan Province, were relatively mild and patients were discharged from the hospital after only a short stay. However, the fasting blood SERO glucose of the infected individuals was found to be slightly elevated because of the state of emergency. The dynamic changes in lymphocyte levels can predict disease status of COVID-19. They are also suggestive of changes in mean platelet volume during disease progression. This suggests that the patients had mild cases of COVID-19. However, because there is no effective drug treatment for COVID-19, it is important to detect and identify severe cases from mild cases early.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.